WSI Co., Ltd.
Financials
Valuation Metrics
WSI Co., Ltd.'s Market Cap is ₩480B. At end of 2025 it was ₩1218B. Ranked #1731 of 2,410 in KR market (top 72%), #1048 of 1,631 on KOSDAQ (top 64%), #71 of 94 in Health Care Equipment & Services (top 76%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 48.03B KRW | KR#1,731/2,410 Sec#71/94 |
| Revenue | 50.77B KRW | KR#1,776/2,410 Sec#53/94 |
| Net Income | -1.13B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 88.94B KRW | KR#1,869/2,410 Sec#57/94 |
| Net Assets | 63.51B KRW | KR#1,752/2,410 Sec#54/94 |
| Employees | 33 | KR#2,172/2,410 Sec#85/94 |
| Value | ||
| P/B | 0.76x | KR#1,289/2,410 Sec#30/94 |
| P/S | 0.95x | KR#1,417/2,410 Sec#26/94 |
| EV/EBITDA | 23.71x | KR#1,126/2,410 Sec#37/94 |
| FCF Yield | 4.49% | KR#913/2,410 Sec#27/94 |
| Profitability | ||
| ROE | -1.78% | KR#1,673/2,410 Sec#57/94 |
| ROA | -1.27% | KR#1,699/2,410 Sec#57/94 |
| Op. Margin | 5.14% | KR#945/2,410 Sec#39/94 |
| Revenue Growth | 1.62% | KR#1,410/2,410 Sec#71/94 |
| Financial Health | ||
| Debt Ratio | 40.04% | KR#786/2,410 Sec#41/94 |
| Total Debt | 21.50B KRW | KR#1,350/2,410 Sec#38/94 |
| FCF | 2.16B KRW | KR#1,069/2,410 Sec#31/94 |
| Cash | 7.70B KRW | KR#1,829/2,410 Sec#61/94 |
| Current Ratio | 2.74x | KR#616/2,410 Sec#37/94 |
| Net Debt/EBITDA | 5.29x | KR#1,039/2,410 Sec#39/94 |
| Performance | ||
| 1Y Return | -47.05% | KR#1,771/2,410 Sec#62/94 |
| 1M Return | -21.56% | KR#1,789/2,410 Sec#76/94 |
| From 52W High | -76.86% | KR#2,232/2,410 Sec#89/94 |
| 1Y MDD | -74.14% | KR#2,122/2,410 Sec#83/94 |
| Trading | ||
| Volume | 97,278 shares | KR#515/2,410 Sec#20/94 |
| Trading Value | 112.0M KRW | KR#1,305/2,410 Sec#53/94 |
| Foreign Own. | 5.56% | KR#783/2,410 Sec#23/94 |
| Per Share | ||
| EPS | -27 KRW | KR—/2,410 Sec—/94 |
| BPS | 1,530 KRW | KR#2,190/2,410 Sec#79/94 |
Company Info
Established in 2016, WSI was listed on KOSDAQ in 2020 following its merger with IBKS No.10 Special Purpose Acquisition Company. The company's main business is the distribution of spinal and joint medical devices. In 2024, WSI acquired a 67% stake in pharmaceutical company Introbio Pharma, adding pharmaceutical manufacturing and R&D, with plans to acquire an additional 10% in the first half of 2025. Headquartered in Songpa-gu, Seoul, WSI is also entering the cardiovascular interventional medical device market from 2024 through collaboration with a global cardiac disease medical device company.